Therapy of polymyositis and dermatomyositis

High-dose oral prednisone (at an initial dose of 1mg/kg/day) is the mainstay of therapy for PM/DM, and should be subsequently tapered slowly based on patients’ clinical response. First-line combination of prednisone with intravenous immunoglobulins may be considered in patients with PM/DM-related severe systemic complications, especially in the subgroup exbititing life-threatening esophageal involvement. In patients who failed to respond to prednisone, the first-line immunosuppressive therapy includes methotrexate or azathioprine. Intravenous immunoglobulin therapy should be considered in patients in whom those cytotoxic drugs are contraindicated. In patients who failed to respond to prednisone, methotrexate or azathioprine, there is no general clinical consensus, although the options more often include: combined therapy of methotrexate and azathioprine, mycophenolate mofetil or rituximab. To date, TNF-⍺ antagonists should not be considered in PM/DM patients, as both efficacy and safety concerns have been markedly raised in anti-TNF-⍺ agent-treated PM/DM patients.

In this issue

Inflammatory or necrotizing myopathies, myositides and other acquired myopathies, new insight in 2011

Benveniste O et al., Paris, France

Observations on the classification of the inflammatory myopathies

Hilton-Jones D, Oxford, United Kingdom

Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis

Gherardi RK, Créteil, France

Sporadic inclusion body myositis: conformational multifactorial aging-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau

Askanas V et al., Los Angeles, USA

Pathophysiology of inflammatory and autoimmune myopathies

Dalakas MC, Philadelphia, USA

Myositis or dystrophy? Traps and pitfalls

Benveniste O et al., Paris, France

Therapy of polymyositis and dermatomyositis

Marie I, Rouen, France